News SMC Accepts First Drug to Improve Survival in Uveal Melanoma by Medscape • 2026/07/14 • 0 Comments Scotland approves tebentafusp for metastatic uveal melanoma, a rare eye cancer with a median survival of around 12 months. Medscape News UK